New drug safety check for liver patients

NCT ID NCT07559474

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arizona Clinical Trials - the Institute For Liver Health

    RECRUITING

    Chandler, Arizona, 85225, United States

  • Orlando Clinical Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

  • Pinnacle Clinical Research

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Texas Liver Institute - American Research Corporation

    RECRUITING

    San Antonio, Texas, 78215, United States